Compare Freshworks Inc (FRSH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Mesoblast Limited — how do they compare? Freshworks Inc trades at $12.63 (market cap $3.22B), while Mesoblast Limited trades at $16.5 (market cap $2.20B). The key difference: Freshworks Inc is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| FRSH | MESO | |
|---|---|---|
Market Cap | $3.22B | $2.20B |
Sector | Technology | Technology |
52-Week High | $13.97 | $20.96 |
52-Week Low | $6.88 | $12.88 |
Enterprise Value | $2.59B | $2.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $12.68, up 5.93% with bullish technical signals and strong fundamental momentum. The company reported Q2 2026 revenue of $237.4 million, beating estimates with 16% YoY growth, achieving its first GAAP profitability quarter. Analyst consensus shows 50% buy ratings with a $16.50 price target, representing 30% upside potential. Recent FedRAMP certification and Gartner leadership recognition strengthen the company's competitive positioning in AI-powered service operations.
The outlook remains positive with accelerating revenue growth and improving profitability, though valuation multiples remain elevated. Key risks include execution challenges in multi-product expansion and competitive pressure in the SaaS sector. The stock presents a compelling opportunity for growth investors seeking exposure to the enterprise software market with improving fundamentals and strong analyst support.
MESO trades at $16.78, down 0.83% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong revenue growth with Ryoncil generating $115 million in its first full year, though it remains unprofitable with a -144.33% net income margin. Recent developments include achieving Phase 3 trial targets for chronic back pain and securing a $50 million non-dilutive facility.
MESO presents a high-risk, high-reward opportunity with significant commercial traction but persistent losses. The bullish analyst consensus and recent regulatory progress support upside potential, though profitability concerns and high P/S ratio of 30.52 warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
